Fulgent Genetics (FLGT) EBIT (2015 - 2026)

Fulgent Genetics has disclosed EBIT across 12 years of filings, most recently posting -$34.6 million for Q1 2026.

• EBIT for Q1 2026 came in at -$34.6 million, down 74.9% year-over-year; the trailing twelve-month figure through Mar 2026 was -$70.2 million (up 2.41% YoY), and the FY2025 annual result was -$14.7 million, up 80.11% from the prior year.
• EBIT came in at -$34.6 million for Q1 2026 at Fulgent Genetics, down from -$500000.0 in the prior quarter.
• In the past five years, EBIT ranged from a high of $201.9 million in Q1 2022 to a low of -$151.1 million in Q4 2023.
• The 5-year median for EBIT is -$17.1 million (2024), against an average of -$8.4 million.
• Across the five-year window, EBIT slumped 18990.12% in 2023 and jumped 96.9% in 2025, its largest moves.
• Fulgent Genetics' EBIT stood at $800000.0 in 2022, then plunged by 18990.12% to -$151.1 million in 2023, then soared by 89.32% to -$16.1 million in 2024, then surged by 96.9% to -$500000.0 in 2025, then tumbled by 6824.4% to -$34.6 million in 2026.
• The last three EBIT figures came in at -$34.6 million (Q1 2026), -$500000.0 (Q4 2025), and -$15.4 million (Q3 2025), per Business Quant data.